looking very promising

  1. 4.6k
    Posts

    All the correct boxes getting ticked off, at the moment

    I hold

    Dyor

  2. 4.6k
    Posts

    Cash position is ok

  3. 6.1k
    Posts

    I think stock has a bright future....I bought my kids quite a bit over the past year or so.
    From memory when they were known as PRR.

  4. 4.6k
    Posts

    Let’s hope 2019 is the year

  5. 7.2k
    Posts

    toot toot ... all aboard ... the trains leaving the station

  6. 7.2k
    Posts

    toot toot ... another easy 15.52% today ;)

  7. 7.2k
    Posts

    finished 20.69% up for the day ... although it got higher during the day ... Check yesterday's announcements.
    You're welcome :)

  8. 7.2k
    Posts

    another +4.29% today ... go you good thing

  9. 7.2k
    Posts

    up another 9.72% so far today ... you've been listening to your Uncle Marcus & buying ... good to see ;)

  10. 7.2k
    Posts

    another +3.9% ... so that's a solid gain of 25% for the month ... beep beep toot toot

  11. 7.2k
    Posts

    up another +14.1% today ... please tell me that you bought & also made +50% this month ... anyone?

    Immutep reports positive data from ongoing trial into cancer drug efti

    Biotechnology company Immutep (ASX: IMM) is set to unveil interim data from its ongoing Phase 2 TACTI-002 study into its efti drug at the 34th German Cancer Congress in Berlin, Germany taking place today.

    The trial was recently expanded after the company announced positive clinical data and said it would recruit more patients for the third stage of TACTI-002.

    Immutep’s study has reportedly recorded that 47% of 1st line non-small cell lung cancer patients and 33% of 2nd line head and neck squamous cell carcinoma patients, reported encouraging responses.

    The company’s chief executive officer Marc Voigt declared that seeing substantial response rates from the combination therapy was “very encouraging”, particularly in light of the good safety profile efti has already established in previous studies.

    Speaking at the congress later today, principal investigator Dr Bernhard Doger will present the latest results from Immutep’s study into its lead product candidate eftilagimod alpha, or efti for short – a soluble LAG-3 protein, as part of a combination treatment with another drug called Keytruda, manufactured by pharma giant Merck.

    This mechanism plays a vital role in the regulation of the T cell immune response and Immutep is confident it can develop an effective treatment option able to combat various cancers.

    Immutep is hopeful that activation of antigenpresenting cells (APC) and subsequent T cell recruitment with efti may lead to stronger anti-tumour responses than observed with pembrolizumab alone.

    “The results we are seeing from our TACTI-002 trial are highly encouraging, with 47% of first-line non-small cell lung cancer patients responding,” said Dr Frederic Triebel, chief scientific and marketing officer of Immutep.

    “These results are remarkable given that usually, only 20% of patients respond to pembrolizumab monotherapy, if not preselected for high PD-L1 expression.

    “Interestingly, patient responses are being seen in all three PD-L1 expression level groups, meaning the combination treatment seems to work even in patients not expected to respond to pembrolizumab monotherapy,” Mr Triebel said.

    Progressing efti
    Immutep’s ongoing trial in collaboration with Merck is evaluating the combination of efti with Keytruda in up to 109 patients that receive 200 mg of pembrolizumab every three weeks, along with 30 mg of efti every two weeks for the first eight cycles and every 3 weeks thereafter.

    The trial itself is a Simon’s two-stage, open-label, single-arm study with patients participating in three distinctive parts.

    In part A, Immutep is looking into first-line non-small cell lung cancer; in part B, second line cell lung cancer and in part C, second-line head and neck squamous cell carcinoma.

    Immutep shares gained 18% in early morning trade to $0.46.

    https://smallcaps.com.au/immutep-reports-positive-data-ongoing-trial-cancer-drug-efti/

  12. 7.2k
    Posts

    down 6.02% today ... thats still a 44.02% gain month on month.

    when profit takers take their profits ... it that the buying dip you were waiting for?

  13. 926
    Posts

    Marcus2000 "toot toot ... all aboard ... the trains leaving the station" @30c

    Currently @13.5c

  14. 7.2k
    Posts

    LOL ... conditional orders ... sold for a 40% profit ... not bad, eh?

    I can recommend IMM for your watch list :D

  15. 926
    Posts

    So you partook in a pump and dump and did a "toot toot" to suck in the punters.

  16. 7.2k
    Posts

    clown ... posting that a stock was going to rise ... and then watching it rise 50% in a month is not a pump & dump ... its sharing my good stock picks.

    You AUL guys are getting desperate ... lol

  17. 926
    Posts

    A stock tip where the price halves?

  18. 7.2k
    Posts

    LOL ... IMM rose 50% over the month. thats the truth ... I can see that you're an amateur and need the SELL signal too haha

    I told you to sell AUL when it came out of month's long trading halt at 0.30 ... but you ignored that.

  19. 926
    Posts

    I am not the only one who reads these forums, I am sure there are many amateurs who read it. You have been exposed for the toot tooting ramping speculator that you are.

  20. 7.2k
    Posts

    toot toot and it went up 50% in the month. You should listen to your Uncle Marcus :D

    hilarious.

  21. 1.6k
    Posts

    Most interesting chart when you look way back.

Your browser is too old for TopStocks and not secure. Please update your browser